Evaluating the efficacy of short duration Mitomycin C in safe surgery system trabeculectomy combined with cataract surgery

Figures & data

Table 1 Baseline characteristics of patients undergoing combined surgery augmented with intraoperative 0.2 mg/ml MMC for 1-minute vs 2-minutes

	MMC
	Study group (1 minute)	Control group (2 minutes)	P-value
Number of cases	41	22
Age (years)	64.02±8.45	61.36±8.53	0.243* (NS)
Gender, n (%)
Male	19 (46.3)	13 (59.1)	0.484^‡ (NS)
Female	22 (53.7)	9 (40.9)
Type of glaucoma, n (%)
POAG	22 (53.7)	8 (36.4)	0.296^‡ (NS)
PACG	19 (46.3)	14 (63.6)
Minimum follow-up period (months)	12	12

Notes: Data expressed as mean±SD or median (min–max), P<0.05, statistically significant. *Obtained using Independent t-test; ^‡Obtained using chi-Square test of homogeneity

Abbreviations: MMC, Mitomycin C; NS, non significant; PACG, Primary angle Closure Glaucoma; POAG, Primary Open Angle Glaucoma.

Table 2 Comparison of clinical parameters in patients undergoing combined surgery augmented with intraoperative 0.2 mg/ml MMC for 1-minute vs 2-minutes

		MMC
		Study group (1 minute)	Control group (2 minutes)	P-value
IOP (mmHg)	Pre-operative	29.05±3.27	30.50±3.02	0.084*(NS)
	Post-operative	19.80±2.41	17.27±3.24	0.003*(S)
P-value^†		<0.001 (S)	<0.001 (S)
LogMAR	Before	1.85±1.58	1.69±1.50	0.688*(NS)
	After	1.27±1.51	1.30±1.35	0.949*(NS)
P-value^†		<0.001 (S)	0.001 (S)
Number of AGM, median (Range)
	Before	2 (1–4)	3 (1–4)	0.147^Ŧ(NS)
	After	1 (0–2)	0 (0–2)	0.004^Ŧ(S)
P-value^‡		<0.001 (S)	<0.001 (S)
% reduction of IOP		31.33±9.06	43.32±9.38	<0.001*(S)

Notes: Data expressed as mean±SD or median (min–max), P<0.05, statistically significant; ^†Obtained using Paired t-test; ^‡Obtained using Wilcoxon signed rank test; *Obtained using Independent t-test; ^ŦObtained using Mann-Whitney U-test for independent samples.

Abbreviations: AGM, anti-glaucoma medication; IOP, intraocular pressure; MMC, Mitomycin C; NS, non significant; S, significant.

Table 3 Success achieved in patients undergoing combined surgery augmented with intraoperative 0.2 mg/ml MMC for 1-minute vs 2-minutes

Criteria	Type of success	MMC administered at
		Study group (1 minute)	Control group (2 minutes)	P-value*
IOP ≤21 mmHg, n (%) IOP ≤18 mmHg, n (%)	Without medication (CS)	10 (24.4)	15 (68.2)	0.004 (S)
	With medication (QS)	23 (56.1)	5 (22.7)
	With or without medication (OS)^†	33 (80.5)	20 (90.9)
	Without medication (CS)	7 (17.1)	14 (63.6)	0.017 (S)
	With medication (QS)	8 (19.5)	1 (4.5)
	With or without medication (OS)^††	15 (36.6)	15 (68.2)

Notes: P<0.05, statistically significant. ^†Eight patients in the 1 minute group and two in the 2 minute group had IOP >21 mmHg; ^††Twenty-six patients in the 1 minute group and seven in the 2 minute group had IOP >18 mmHg; *Obtained using chi-square test of homogeneity.

Abbreviations: CS, complete success; IOP, intraocular pressure; MMC, Mitomycin C; NS, non significant; OS, overall success; QS, qualified success; S, significant.

Table 4 Post-operative complications in patients undergoing combined surgery augmented with intraoperative 0.2 mg/ml MMC for 1-minute vs 2-minutes

Complications, n (%)	MMC
	Study group (1 minute)	Control group (2 minutes)	P-value
Bleb massage	3 (7.3)	0	—
Bleb needling	2 (4.9)	2 (9.1)	0.911 (NS)
Bleb revision	0	1 (4.5)	—
Fibrin	4 (9.8)	4 (18.2)	0.575 (NS)
Hypotony	1 (2.4)	1 (4.5)	0.999 (NS)

Note: P<0.05, statistically significant.

Abbreviations: MMC, Mitomycin C; NS, non significant; S, significant.

Figure 1 Kaplan-Meier plots for overall success in two treatment groups.